US · MD · MEDICAL - CARE FACILITIES
Pediatrix Medical Group, Inc. (MD) intrinsic value and stock valuation
$30.22as of 2026-11-21 · Mkt cap 2.13B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Pediatrix Medical Group, Inc. DCF and intrinsic value
InvestorsCraft values MD with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from MD’s statements →
Pediatrix Medical Group, Inc. Graham Number
Graham Number: $21.05d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- LifeStance Health Group, Inc. (LFST) $13.82
- Organon & Co. (OGN) $13.89
- Acadia Healthcare Company, Inc. (ACHC) $34.60
- Guardian Pharmacy Services, Inc. (GRDN) $46.94
- Addus HomeCare Corporation (ADUS) $122.50
- Aveanna Healthcare Holdings Inc. (AVAH) $11.01
- Astrana Health, Inc. (ASTH) $28.90
- Ardent Health Inc. (ARDT) $15.08
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.91B | $2.01B | $1.99B | $1.97B | $1.91B |
| Operating income | $231.1M | -$-68.71M | $7.32M | $172.7M | $202.9M |
| Net income | $165.4M | -$-99.07M | -$-60.41M | $66.3M | $131M |
| EPSd | $1.94M | -$-1.19M | -$-734.91K | $788.5K | $1.52M |
| Operating cash flow | $271.1M | $206.6M | $137.3M | $166.9M | $76.7M |
| Capital expenditure | -$-18.46M | -$-22.02M | -$-33.33M | -$-29.71M | -$-32.25M |
| Free cash flow | $252.6M | $184.6M | $104M | $137.2M | $44.5M |
| Total assets | $2.25B | $2.15B | $2.22B | $2.35B | $2.72B |
| Total debt | $660.3M | $662.3M | $701.7M | $717.1M | $1.07B |
| Net debt | $285.1M | $432.4M | $628.4M | $707.3M | $678.4M |
| Total equity | $865.9M | $764.9M | $849.1M | $891.6M | $896.7M |
| Cash and short-term investments | $499.7M | $348.5M | $177.7M | $103.1M | $487.1M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.91B | $2.01B | $1.99B | $1.97B | $1.91B |
| Cost of revenue | $1.44B | $1.56B | $1.57B | $1.5B | $1.4B |
| Gross profit | $471.9M | $454.3M | $421.6M | $467M | $513.2M |
| Research and development expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Selling, general and administrative expenses | $240.8M | $238.4M | $227.5M | $231.4M | $263.4M |
| Other expenses | $0.00 | $284.6M | $186.7M | $63M | $47M |
| Operating expenses | $240.8M | $523.1M | $414.2M | $294.4M | $310.3M |
| Cost and expenses | $1.68B | $2.08B | $1.99B | $1.8B | $1.71B |
| Interest income | $19.1M | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $36M | $40.7M | $42.1M | $39.7M | $68.7M |
| Depreciation and amortization | $21.8M | $32.2M | $36.2M | $35.6M | $32.2M |
| Ebitda | $274.2M | -$-28.37M | $29.9M | $156.7M | $236.1M |
| Operating income | $231.1M | -$-68.71M | $7.32M | $172.7M | $202.9M |
| Total other income/expenses, net | -$-14.65M | -$-32.63M | -$-55.68M | -$-91.32M | -$-67.69M |
| Income before tax | $216.4M | -$-101.34M | -$-48.36M | $81.4M | $135.2M |
| Income tax expense | $51M | -$-2.27M | $12.1M | $18.8M | $27.2M |
| Net income | $165.4M | -$-99.07M | -$-60.41M | $66.3M | $131M |
| Weighted average shares outstanding | $85.3M | $83.3M | $84M | $83M | $86.4M |
| Weighted average diluted shares outstanding | $85.3M | $83.3M | $82.2M | $84.1M | $86.4M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $499.7M | $348.5M | $177.7M | $103.1M | $487.1M |
| Net receivables | $242.3M | $272.6M | $279.9M | $296.8M | $316M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $763.5M | $639.6M | $483.5M | $428M | $840.6M |
| Property, plant and equipment, net | $73.5M | $78.4M | $145.9M | $140.2M | $135.6M |
| Goodwill and intangible assets | $1.28B | $1.25B | $1.41B | $1.55B | $1.53B |
| Long-term investments | $20.8M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $1.48B | $1.51B | $1.74B | $1.92B | $1.88B |
| Total assets | $2.25B | $2.15B | $2.22B | $2.35B | $2.72B |
| Accounts payable | $37.2M | $46.4M | $34.6M | $31.9M | $36.7M |
| Short-term debt | $38.4M | $33.3M | $36M | $36.5M | $22.2M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $458.9M | $434.1M | $389M | $427M | $427.4M |
| Long-term debt | $621.9M | $629.1M | $665.7M | $680.6M | $1.04B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $921.9M | $953.7M | $981.8M | $1.03B | $1.4B |
| Capital lease obligations | $27.3M | $50M | $77.6M | $76.9M | $63.6M |
| Total liabilities | $1.38B | $1.39B | $1.37B | $1.46B | $1.83B |
| Common stock | $830K | $860K | $840K | $830K | $860K |
| Retained earnings | -$-83.15M | -$-248.54M | -$-149.47M | -$-89.06M | -$-155.39M |
| Accumulated other comprehensive income (loss) | $610K | -$-1.07M | -$-2.21M | -$-3.73M | $1.32M |
| Total equity | $865.9M | $764.9M | $849.1M | $891.6M | $896.7M |
| Total investments | $145.3M | $118.6M | $104.5M | $93.2M | $99.7M |
| Total debt | $660.3M | $662.3M | $701.7M | $717.1M | $1.07B |
| Net debt | $285.1M | $432.4M | $628.4M | $707.3M | $678.4M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $165.4M | -$-99.07M | -$-60.41M | $62.6M | $108M |
| Depreciation and amortization | $21.8M | $33.2M | $36.2M | $35.6M | $32.2M |
| Stock-based compensation | $18.1M | $11.9M | $12.3M | $16.1M | $19M |
| Change in working capital | $41.8M | $88.2M | -$-11.63M | $31.8M | -$-23.36M |
| Accounts receivable | $30.6M | $10.3M | $26.3M | -$-5.54M | -$-72.73M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $28.3M | $51.1M | -$-11.92M | $420K | $21.3M |
| Net cash provided by operating activities | $271.1M | $206.6M | $137.3M | $166.9M | $76.7M |
| Investments in property, plant and equipment | -$-18.46M | -$-22.02M | -$-33.33M | -$-29.71M | -$-32.25M |
| Acquisitions, net | $6.8M | -$-8.17M | -$-6.67M | -$-28.17M | -$-29.93M |
| Net cash used for investing activities | -$-18.3M | -$-35.41M | -$-48.18M | -$-56.95M | -$-53.07M |
| Common stock issued | $3.18M | $3.64M | $4.91M | $5.4M | $6.85M |
| Common stock repurchased | -$-86.68M | -$-1.7M | -$-920K | -$-88.51M | -$-4.72M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-107.49M | -$-14.48M | -$-25.71M | -$-487.55M | -$-760.12M |
| Net change in cash | $145.3M | $156.7M | $63.4M | -$-377.57M | -$-736.45M |
| Cash at end of period | $375.2M | $229.9M | $73.3M | $9.82M | $387.4M |
| Operating cash flow | $271.1M | $206.6M | $137.3M | $166.9M | $76.7M |
| Capital expenditure | -$-18.46M | -$-22.02M | -$-33.33M | -$-29.71M | -$-32.25M |
| Free cash flow | $252.6M | $184.6M | $104M | $137.2M | $44.5M |
Line items
Line items
Line items
About Pediatrix Medical Group, Inc.
Pediatrix Medical Group, Inc. delivers specialized medical services for newborns, expectant mothers, and pediatric patients across the United States and Puerto Rico. The company offers crucial neonatal care to critically ill or prematurely born infants within hospital units, staffed by expert neonatal subspecialists and advanced practice clinicians. For pregnant individuals and their developing babies, Pediatrix provides comprehensive maternal-fetal medicine services in both clinical and inpatient settings, involving specialists such as maternal-fetal medicine physicians, obstetricians, and genetic counselors. Furthermore, the group delivers pediatric cardiology services, addressing both congenital and acquired heart conditions in patients ranging from the fetal stage through adulthood, under the care of dedicated pediatric cardiologists. Beyond these core areas, Pediatrix extends its expertise to various other pediatric subspecialties, including those requiring intensivists, surgeons, and ophthalmologists, and supplies vital support to hospital departments like emergency rooms and labor and delivery units. Established in 1979 in Sunrise, Florida, and formerly known as MEDNAX, Inc. until its renaming in July 2022, the company managed a network of approximately 2,700 physicians as of February 2022.
- CEO
- Mark S. Ordan
- Employees
- 4.12K
- Beta
- 0.66
Included in
Explore
Frequently asked questions
What is the intrinsic value of Pediatrix Medical Group, Inc. (MD)?
Pediatrix Medical Group, Inc. (MD) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is MD undervalued?
MD trades at a price of $30.22 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.